---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-014683"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:13:39.568879+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August

## Summary
- PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.
- Over 100 patients registered in PAPZIMEOS Patient Hub; more than 100 million lives covered by private insurance.
- Submitted Marketing Authorization Application to EMA for zopapogene imadenovec in November 2025.
- Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025.
- Entered credit facility providing up to $125 million non-dilutive financing; received first tranche of $100 million.

## SEC filing metadata
- accession: 0000950103-25-014683
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/0000950103-25-014683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010325014683/dp237316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-014683
- JSON: https://secwatch.observer/filing/0000950103-25-014683.json
- Plain text: https://secwatch.observer/filing/0000950103-25-014683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.